Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Cisplatin + Serplulimab in Advanced EBV-Associated Biliary Tract Cancer
ChiCTR2300071825Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and serplulimab in biliary cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started May 2023; status: recruiting.
02
Drugs
gemcitabinecisplatinserplulimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2300071825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071825.